Astellas Pharma Inc. has described new quinazoline GTPase KRAS (G12D mutant) degradation inducers reported to be useful for the treatment of pancreatic cancer. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. An exemplified compound degraded KRAS(G12D) mutant expressed in human pancreatic AsPC-1 cancer cells (DC50 = 37 nM) in ELISA assays. It inhibited 3D anchorage-independent proliferation of KRAS(G12D) mutant-positive AsPC-1 cancer cells (IC50 = 23 nM) in Celltiter-Glo assays.

Hangzhou Innogate Pharma Co. Ltd. has divulged new NLRP3 inflammasome inhibitors reported to be useful for the treatment of inflammation, cancer, infections and metabolic, respiratory, liver, kidney and autoimmune diseases, among other disorders.

Jiangsu Hengrui Medicine Co. Ltd. has described prodrugs of tolvaptan acting as vasopressin V2 receptor antagonists.

Medshine Discovery Inc. has discovered 5,6,7,8-tetrahydropyridine[3,4-d] pyrimidine compounds acting as GTPase KRAS inhibitors.

Shanghai Visonpharma Co. Ltd. has patented dihydropyrimidine compounds reported to be useful for the treatment of hepatitis B virus (HBV) infections.

Jiangsu Mabwell Health Pharmaceutical R&D Co. Ltd. has synthesized new antibody-drug conjugates (ADC) or antigen binding fragments targeting claudin 18 (CLDN18) and linked to cytotoxic drug reported to be useful for the treatment of cancer.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has presented new Wee1-like protein kinase (Wee1) inhibitors reported to be useful for the treatment of cancer.